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Abstract  
Diabetic peripheral neuropathy affects up to half of diabetic patients. This neuronal damage 
leads to sensory disturbances, including allodynia and hyperalgesia. Many growth factors 
have been suggested as useful treatments for prevention of neurodegeneration, including 
vascular endothelial growth factor family. VEGF-A is generated as two alternative splice 
variant families. The most widely studied isoform, VEGF-A165a is both pro-angiogenic and 
neuroprotective, but pro-nociceptive and increases vascular permeability in animal models. 
Streptozotocin-induced diabetic rats develop both hyperglycaemia and many of the resulting 
diabetic complications seen in patients, including peripheral neuropathy. Here we show that 
the anti-angiogenic VEGF-A splice variant, VEGF-A165b, is also a potential therapeutic for 
diabetic neuropathy. Seven weeks of VEGF-A165b treatment in diabetic rats reversed 
enhanced pain behaviour in multiple behavioural paradigms and was neuroprotective, 
reducing hyperglycaemia-induced activated caspase 3 levels in sensory neuronal subsets, 
epidermal sensory nerve fibre loss and aberrant sciatic nerve morphology. Furthermore, 
VEGF-A165b inhibited a streptozotocin-induced increase in Evans Blue extravasation in 
dorsal root ganglia (DRG), saphenous nerve and plantar skin of the hind paw. Increased 
TRPA1 channel activity is associated with the onset of diabetic neuropathy. VEGF-A165b also 
prevented hyperglycaemia-enhanced TRPA1 activity in an in vitro sensory neuronal cell line 
indicating a novel direct neuronal mechanism that could underlie the anti-nociceptive effect 
observed in vivo. These results demonstrate that in a model of type I diabetes VEGF-A165b 
attenuates altered pain behaviour and prevents neuronal stress, possibly through an effect 
on TRPA1 activity. 
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Introduction 
Diabetes mellitus affects 6.7% of European and 10.5% of the US populations and results in 
a myriad of debilitating complications that constitute an increasing burden on healthcare 
systems. A major complication is diabetic neuropathy, affecting up to 50% of diabetic 
patients [1]. Hyperglycaemia affects sensory afferents, and autonomic and motor nerves [2], 
influencing unmyelinated [3] and myelinated [4] fibre function, leading to autonomic and 
motor dysfunction, and altered proprioception and nociception. Nociceptors are rendered 
more sensitive to activation as a result of changes in the local microenvironment, such as 
compromised vascular perfusion and/or direct actions upon neurons. Sensory neurons are 
particularly susceptible to hyperglycaemic damage, due to a lack of insulin-regulated 
glucose uptake [5], and are also affected by the generation of reactive metabolites such as 
oxidative or glycosylated by-products under hyperglycaemic conditions [6]. Exposure to 
persistently high glucose levels in humans and in rodent models leads to classical signs of 
diabetic neuropathy, axonal atrophy and demyelination, reductions in conduction velocity 
and epidermal innervation, and symptoms of allodynia, (pain in response to normally non-
painful stimuli), hyperalgesia (more severe pain in response to a normally painful stimulus), 
burning, or on-going pain. Sensory neuronal damage and loss may ultimately lead to 
hypoalgesia or anaesthesia [7]. A number of mechanisms have been proposed to underlie 
diabetes-induced neuro-pathology [2, 5], including activation of transient receptor potential 
ankyrin 1 (TRPA1) channels [8], blockade of which attenuates both diabetes-induced 
peripheral neuronal loss and neuropathic pain [9]. 
Neuronal complications are attributed to both microvascular damage and reduction in neural 
trophic support, for example both nerve growth factor (NGF) [10] and vascular endothelial 
growth factor-A (VEGF-A) [11] are reduced. VEGF-A165a is the archetypal pro-angiogenic 
factor that also has neuroprotective capacity in experimental diabetes [12]. The products of 
the vegf-a gene consist of two isoform families; VEGF-Axxxa and VEGF-Axxxb (xxx relates to 
amino acid number), generated by alternative pre-mRNA splicing that differ only in their 
terminal six amino acid sequences. While each family’s predominant isoform, VEGF-A165a 
and VEGF-A165b respectively, is neuroprotective for sensory neurons [13, 14], VEGF-A165a is 
also pro-nociceptive [15]. In contrast, VEGF-A165b is anti-angiogenic and anti-nociceptive yet 
also neuroprotective, in vivo and in vitro, through alternative VEGFR2 activation and 
signalling mechanisms [13, 16-18]. In diabetic neuropathy, intra-epidermal nerve fibre loss 
and the severity of pain are related to the degree of decrease in VEGF and VEGFR2 
expression, suggesting a relationship between VEGF-A and diabetic neuronal damage [19]. 
Therefore we tested the hypothesis that the anti-angiogenic, neuroprotective, anti-
nociceptive VEGF-A isoform, VEGF-A165b, protects against neuronal damage and pain in a 
model of Type I diabetes. Our results are the first to demonstrate that in this diabetes model, 
systemic delivery of recombinant human VEGF-A165b can reverse pain-like behaviours and 
prevent peripheral neuropathy. 
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Research Design and Methods 
1. Experimental animals and procedures. 
Thirty-seven female Sprague Dawley rats (~250g) were used in this study in accordance 
with the UK Home Office Animals (Scientific Procedures) Act 1986 and amendments (2012). 
Experiments were performed in laboratories at the Universities of Bristol (behaviour and 
subsequent tissue analysis, primary culture) and Nottingham (Evans’ Blue), and were 
approved by the Universities of Bristol and Nottingham AWERBs (Animal Welfare and 
Ethical Review Boards). Diabetes was induced with intraperitoneal (i.p.) injection of 
streptozotocin (STZ) (50mg/kg) and one third of an insulin pellet (Linshin, Canada) was 
implanted in the scruff of the neck using the supplied trocar (Linshin, Canada) under 
isoflurane anaesthesia (2-3% in O2) [20]. For the first 24h animals had ad libitum access to 
saturated sucrose solution, animals had ad libitum access to standard chow throughout, 
were regularly weighed, and housing and drinking water regularly checked over the 9 week 
study. Experimental groups were diabetic animals ± saline (i.p. n=14), or recombinant 
human VEGF-A165b (20ng/g body weight, i.p. twice weekly from week 1, n=12) [13] and 
untreated naïve animals (n=11). This twice weekly i.p. dosing regime has proven successful 
in the amelioration of diabetic nephropathy [21], traumatic nerve injury [16] and in vivo 
tumour models [22]. . 
Nociceptive behavioural testing 
Behavioural assessments were carried out on a total of 22 rats. Rats were habituated to the 
behavioural testing environments for 2 weeks (enclosures with metal mesh or Perspex 
floors) and for 10 minutes before the start of each session. The operator was blind to 
treatment throughout. 
Mechanical withdrawal thresholds: von Frey (vF) monofilaments of increasing forces were 
applied to the plantar surface of the hind paws. Each monofilament was applied 5 times to 
generate a force:response (withdrawal) relationship and the 50% withdrawal threshold was 
calculated. Cold nociception: a single drop of acetone was applied to the plantar surface of 
the hind paw 5 times with quantification of licking/shaking nociceptive behaviours [23] 
(positive response = 1, no response = 0, maximum = 5). Heat nociception: withdrawal to 
heat was determined using the Hargreaves test [24]. The intensity of the radiant heat source 
was set and remained constant for the duration of the study. Each hind paw was stimulated 
three times and mean withdrawal latency was calculated. Mechanical and thermal 
nociceptive behaviours were tested weekly throughout the study. Response to a noxious 
chemical stimulus was determined by subcutaneous injection (dorsal surface of hind paw) of 
0.5% formalin prior to diabetes induction [20], and at 2 and 7 weeks after diabetes onset. 
This is a low concentration of formalin, that induces only a slight and brief acute phase (0-15 
min), and no second phase (15-60 min) response in normal rats (Fig. 2D), and does not 
induce prolonged sensitization.  
2. Immunofluorescence and toluidine blue histology  
After 7 weeks, animals were terminally anaesthetized (sodium pentobarbital 60mg/kg i.p.) 
and transcardially perfused, with either phosphate buffered saline (PBS) followed by 4% 
paraformaldehyde in PBS (PFA; pH7.4) for immunofluorescence (n=3/group) or PBS 
followed by 2.5% glutaraldehyde in cacodylate buffered saline (CBS, pH7.4) for sciatic nerve 
myelinated fibre counts (n=3/group). L4&5 DRG and hind paw plantar skin were removed, 
post-fixed overnight (4% PFA at 4oC), and transferred to 30% sucrose overnight at 4oC. 
Tissue was embedded, frozen and stored at -80oC until sectioning and processing. 
Cryosections were cut at 8µm (DRG) or 20µm (plantar skin), mounted on slides (Superfrost 
plus, VWR international), washed (PBS), and incubated in blocking solution (5% bovine 
serum albumin, 10% foetal calf serum, 2h at room temperature) followed by primary 
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antibodies (see below) in blocking solution, overnight at 4oC. Sections were washed with 
PBS, incubated in secondary antibodies in PBS + 0.2% Triton X-100 at room temperature 
for 2h, coverslipped in Vectorshield mounting media (Vector Laboratories; +DAPI). Sciatic 
nerve was removed, post-fixed in 2.5% glutaraldehyde and CBS (pH7.4) at 4oC until 
processed by washing in CBS, incubation in 1% osmium tetroxide in 0.1M CBS, and CBS 
wash. Samples were dehydrated, embedded in resin, and semi-thick sections (1µm) stained 
with toluidine blue [25].  
Primary antibodies and dilutions were: polyclonal rabbit, anti-activated caspase III (AC3; 1 in 
500, NEB); monoclonal mouse, anti-NeuN (1 in 200, Millipore); isolectin B4-biotin conjugated 
(IB4; 1 in 500, Sigma-Aldrich); monoclonal mouse, anti-neurofilament 200 (NF200; 1 in 
1000, Sigma-Aldrich); polyclonal rabbit anti-PGP9.5 (1 in 200, Ultraclone); polyclonal rabbit 
anti-NSE-1 (neuron-specific enolase-1, 1 in 1000, VWR); monoclonal rabbit anti-VEGF 
receptor 2 (Cell Signaling 55B11 1 in 200); goat polyclonal anti-actin (Santa Cruz SC-1616 
2µg/ml). Secondary antibodies for immunofluorescence were Alexa Fluor 488-conjugated 
chicken anti-mouse, Alexa Fluor 555-conjugated donkey anti-rabbit and streptavidin-
conjugated Alexa Fluor-488 (all Invitrogen, UK). Controls included replacement of primary 
antibody with species and concentration-matched IgG or pre-incubation with appropriate 
blocking peptide (activated/cleaved caspase III, NEB). Secondary antibodies for Western 
blotting were Licor IRDye 680RD donkey anti-rabbit, 1 in 5000 and donkey anti-goat Licor 
IRDye 800CW, 1 in 5000. 
For DRG (n=3) and plantar skin (n=3) analyses, a minimum of 5 randomly selected non-
serial images from at least 5 sections from each animal in each treatment group, at a 
magnification of x20 (plantar skin) or x10 (DRG). In skin all PGP9.5 positive nerve fibres 
were counted per image area (35mm2). In DRG the mean number of neurons (identified by 
NeuN/Neurofilament) counted per animal was ~800. Myelinated axon counts were 
performed on a minimum of 5 random non-serial images per section, 5 sections per animal 
(a mean of ~450 axons per animal).  
3. Evans Blue extravasation and calculation of clearance.  
In vivo vascular dysfunction was evaluated using Evans’ Blue dye perfusion [26] in an 
additional 15 rats. Seven week diabetic + saline, diabetic + VEGF-A165b and age-matched 
controls (n=5 each) were terminally anesthetized (ketamine/medetomidine i.v. 50 mg/kg) 
and infused with Evans Blue dye i.v. (Sigma-Aldrich, 45 mg/kg) Two minutes post-infusion, 
0.2mL arterial blood was withdrawn, followed by subsequent 0.1mL withdrawals every 15 
minutes for 2 hours. After 2 hours of Evans’ Blue dye circulation, 0.2mL blood was 
withdrawn from the heart followed by cardiac perfusion of 50mL saline at 120mmHg.  DRG 
L3, 4 & 5, left saphenous nerve and left plantar skin were excised and weighed to determine 
their wet weight. Tissue was then dried at 70˚C overnight and weighed to determine dry 
weight. To determine Evans’ Blue extravasation, dried tissue was incubated in 0.15mL 
formamide (Sigma Aldrich) at 70˚C overnight. Blood samples were centrifuged at 12,000 
rpm for 45 minutes at 4˚C, and the supernatant from tissue and blood samples were 
analysed at 620nm. Evans’ Blue clearance was calculated as Evans’ Blue wet weight solute 
flux (µg/h/g) divided by time-averaged plasma Evans Blue concentration (µg/mL) multiplied 
by total time (h). 
4. Primary dorsal root ganglion neuronal culture 
Adult rat Wistar rats were perfused transcardially with PBS under anaesthesia (sodium 
pentobarbital 60mg/kg, i.p.) and T1-L6 DRG were extracted, enzymatically and mechanically 
dissociated, and cultured on poly-l-lysine/laminin coated glass coverslips in Ham’s F12 plus 
1x N2 supplement (Life Technologies), 0.3% BSA + 1% pen/strep. After cell attachment, 
mitotic cells were inhibited with 30µg/mL 5-fluoro-2’-deoxyuridine. Cultures were pre-treated 
overnight (18hrs) with 2.5nM VEGF-A165b or vehicle as previously described [13], then 
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incubated under either high glucose (final concentration 50mM) or a basal neuronal culture 
glucose level (10mM) [27] for 6h. Proportions of activated caspase III (AC3)-positive DRG 
neurons (co-labelled NSE-1) were determined by immunofluorescence as previously 
described.  
Epifluorescence imaging was performed on a Nikon Eclipse E400 microscope equipped with 
x40 objective lens and a Nikon DN100 camera. Confocal imaging was performed on Leica 
TCS SPE confocal microscope. Images were acquired using x63 oil immersion objective 
lens and Leica application suite. All imaging was performed at room temperature. Computer-
aided analysis of images was performed using ImageJ (NIH, Bethesda, MD; available at 
http://rsb.info.nih.gov/nih-image). In each instance the analyser was blinded to treatment 
group. 
5. Immortalised neuronal cell line (50B11) culture 
TRPA1 channel activation was assayed in immortalized embryonic rat sensory neurons, 
50B11, in line with the requirements of UK legislation and the 3Rs. 50B11 cells were 
maintained under previously published conditions [28]: Neurobasal media (Invitrogen), 
supplemented with foetal bovine serum (10%), glutamine (0.55mM), B27 supplement and 
additional glucose (11mM) making the total glucose concentration 36mM (basal glucose). 
Incubation with lower, more physiological glucose concentrations in vitro affects their 
neuronal phenotype, impairing normal neurite outgrowth (Bestall et al, unpublished data). 
For these cells therefore, this high glucose level (compared with in vivo) is a requirement for 
normal function, and therefore considered “basal”. 50B11 cells were plated into 96 well 
plates and incubated for 2 days, then differentiated with 75µM forskolin maintained in the 
medium for at least 24h, after which cells were incubated for 24h with the following reagents: 
2.5nM VEGF-A165b, PBS vehicle, 200nM PTK787 (VEGFR2 inhibitor, in 0.02% DMSO), 
0.02% DMSO control, 8.05µg/mL DC101 (rat monoclonal anti-mouse VEGFR2, BioXcell) or 
8.05µg/mL rat IgG control. In vitro high glucose conditions were maintained for 24h, with 
addition of a further 30mM glucose (final concentration 66mM) to the media, or 30mM 
mannitol to control for osmotic effects. After differentiation and incubation under 
experimental conditions, cells were loaded with Fluo-4 (Invitrogen) in Hank’s balanced salt 
solution containing 20mM HEPES and 2mM CaCl2 for 1h. The TRPA1 agonist allyl 
isothiocyanate (AITC in PBS, Sigma-Aldrich) was used to activate TRPA1 channels and 
calcium fluorescence measured in a Wallac 1420 Victor 3 multi-plate reader (Perkin Elmer) 
at 37oC. A TRPA1 antagonist, AP-18 (Tocris, UK) was used to determine the specificity of 
AITC in this assay. Baseline readings were determined prior to stimulation by 100µM AITC, 
and after AITC application, sequential fluorescence emission values were recorded. The 
time of the first reading was ~25s after AITC application.  
The effect of high glucose treatment or 300µM AITC for 24h (application twice at 12h 
intervals) on AC3 in 50B11 cells was also determined. After 24h differentiation with forskolin, 
50B11 cells were treated for 24h, then fixed and stained for AC3 as previously detailed. 
Total image AC3 fluorescence intensity was expressed over total DAPI fluorescence (total 
cell nuclei) intensity to account for differences in cell number.  
6. Western blotting 
The presence of VEGF receptor 2 (VEGFR2) in 50B11 cells was confirmed with Western 
blotting. 50B11s grown in either normal (36mM) or high (66mM) glucose were lysed and 
protein extracted in the presence of phenylmethylsulfonyl fluoride and proteinase inhibitors. 
Protein lysate as electrophoresed on 10% SDS-PAGE gels, blotted on PVDF membrane by 
wet transfer and incubated for 24 hours at 4oC with anti-VEGFR2 antibody in blocking buffer 
(Tris buffered saline, 0.1% Tween-20, 5% bovine serum albumin). After secondary antibody 
incubation for 1 hr at room temperature in blocking buffer, blots were imaged using a Licor 
Running title: VEGF-A165b prevents diabetic neuropathic pain	  
	   7	  
imaging system. Protein loading differences between wells were controlled for by probing of 
for VEGFR2 expression.  
7. Data extraction and statistical analysis 
Acquired data were processed and graphed using Microsoft Excel 2007 and/or GraphPad 
Prism v5-6. Data are shown as mean±SEM unless otherwise stated. Three or more groups 
were compared using between subjects one or two way ANOVA with post-hoc Bonferroni 
tests, and two groups were compared using Wilcoxon signed rank tests, as stated in the 
Figure legends. Representative data values for outcome measures are given in Table 1. The 
effect sizes for treatment compared to diabetes alone shown in Table 1 were calculated from 
the means, standard deviations and sample sizes given in the Table, using GPower 
(http://www.gpower.hhu.de/).  
Results 
Recombinant human VEGF-A165b prevented diabetic neuropathic pain in vivo 
As previously reported [20], STZ-injection with low dose insulin supplementation resulted in 
a maintained hyperglycaemia (Fig 1A) and body weight (Fig 1B) over the duration of the 
study. Also as previously reported [20], STZ treatment with low-dose insulin supplementation 
resulted in a rapid (1-2 weeks) and significant lowering of mechanical-stimulus withdrawal 
thresholds (mechanical allodynia), maintained for the duration of the study (Fig. 1C). In 
addition, diabetic animals developed significant cold allodynia (Fig. 1D), and heat 
hyperalgesia (Fig. 1E). Biweekly, systemic VEGF-A165b treatment significantly reversed the 
initial changes in mechanical allodynia (Fig. 1C), prevented the onset of cold allodynia (Fig. 
1D) and reversed the heat hyperalgesia (Fig. 1E). Chemical nociception in response to a low 
dose of formalin (0.5%) was enhanced in diabetic animals, measured at week 2 (Fig. 1F). 
This enhanced acute chemo-nociception at week 2 was ameliorated by VEGF-A165b 
treatment (Fig. 1F). The significant increase in chemo-nociceptive behaviour in diabetic rats 
was lost by week 7 (Fig. 1F). No significant second phase behaviour (indicative of central 
sensitization) was observed in response to formalin in any animals at any time point. 
Recombinant human VEGF-A165b protected sensory neurons against hyperglycaemic 
damage in vivo and high glucose treatment in vitro 
Incubation of adult rat primary DRG neurons in increased glucose conditions for 6h resulted 
in an increase of the percentage of neurons expressing activated caspase 3 (AC3) (Fig. 2A 
& B; basal glucose = 26.3±3.5%, high glucose = 53.0±6.1%), indicating neuronal stress 
under these conditions, which was blocked by recombinant human VEGF-A165b (Fig. 2B; 
high glucose ± VEGF-A165b = 35.0±2.3%). VEGF-A165b alone had no effect on expression of 
AC3. We then determined whether VEGF-A165b could protect sensory neurons against 
damage in vivo in the rodent model of Type I diabetic neuropathy in which VEGF-A165b had 
inhibited pain responses (Fig. 1). Figure 2C & D shows that the number of AC3-expressing 
L5 (Fig. 2C-F) and L4 (not shown) DRG neurons was increased in diabetic rats in vivo 
compared to naïve and this was reduced by VEGF-A165b treatment, predominantly in the 
small diameter population (Fig. 2E). Furthermore, there was an increase in the total number 
of smaller DRG neurons (<400µm2 PGP9.5-positive DRG neurons) within the diabetic 
animals versus age-matched controls (Fig. 2F). VEGF-A165b treatment prevented this 
increase in number of smaller DRG neurons. Co-staining demonstrated that there was 
increased AC3 staining in nociceptive small IB4-reactive neurons (Fig. 3A & B) and also in 
myelinated neurons (neurofilament (NF200)-positive Fig. 3C & D). VEGF-A165b treatment 
reversed the increased AC3 expression in both neuronal groups (Fig. 3B & D). A reduction 
in epidermal innervation is a diagnostic hallmark of diabetic neuropathy [29]. Seven weeks 
after STZ injection, there were fewer PGP9.5-positive nerve terminals at the 
dermal/epidermal border and entering the epidermis in hind paw plantar skin (Fig. 4A, 
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arrows), which was reversed with VEGF-A165b treatment at week 7 (Fig. 4B). Langerhans 
cells, inflammatory cells reported to increase in number in diabetic patients [30], were also 
increased in the epidermis of diabetic rats at week 7 (Fig. 4A, arrowheads) and this was also 
significantly reduced by VEGF-A165b treatment (Fig. 4C). 
Morphological changes, including axon diameter and myelin structure of sciatic nerve, have 
been reported in SOD1-/- and db/db mice [25], and are thought to result from hyperglycaemic 
damage of the neuronal myelin through either structural or compositional alterations [25]. In 
diabetic rats, we found similar changes (Fig. 5A), in that there was an overall reduction in 
myelinated axon cross-sectional area in the sciatic nerve (Fig. 5B) compared to naïve 
animals, and this was reversed by VEGF-A165b. The reduction in the number of ‘medium 
sized’ fibres with cross-sectional areas <90µm2 but >30µm2 (and an increase in the number 
of small myelinated fibres with areas <30µm2 (Fig. 5C), may reflect a reduction in larger axon 
size resulting in an apparent increase in the number of smaller myelinated fibres. Again, as 
previously observed [25], there was an increase in the number of axons with gross 
indications of aberrant myelin morphology in diabetic animals (Fig. 5D &E; asterisks in 5A), 
which was reversed by VEGF-A165b (Fig. 5E). Furthermore, NF200-positive neuronal cell 
bodies in L5 DRG had significantly smaller cross-sectional areas in the diabetic group 
compared to the naïve age-matched control group (Fig. 5F & G). VEGF-A165b treated 
prevented this reduction in size of the neurofilament sensory neuronal population. 
VEGF-A165b prevented STZ-induced increase in Evans Blue clearance in DRG, the 
saphenous nerve and hind paw plantar skin. 
There was a significant increase in Evans Blue clearance in DRG (Fig. 6A), and saphenous 
nerve (Fig. 6B) in diabetic animals and with a trend for an increase in the plantar hind paw 
skin (Fig. 6C) compared to naïve animals. Biweekly treatment of VEGF-A165b significantly 
reduced the clearance in these tissues compared to vehicle-treated animals (Fig. 6A-C).  
TRPA1-mediated calcium fluorescence was affected by VEGF-A165b in vitro. 
Diabetic neuronal terminal loss and pain are suggested to occur, at least in part, through 
sustained activation of C-fibre nociceptors [3] particularly those expressing the non-selective 
cation channel, TRPA1 [9]. Immortalized rat sensory neurons (50B11 [28]) express 
nociceptive channels such as functional TRPV1, P2X [28], TRPA1 (Fig. 7A), and also 
receptors for VEGF (Fig. 7B). VEGF receptor-2 expression was not changed under high 
glucose conditions (not shown). The TRPA1 agonist AITC evoked a concentration-
dependent increase in intracellular calcium levels in 50B11 cells maintained under basal 
glucose concentrations [28] (Fig. 7A). AITC has been shown to activate TRPV1 as well as 
TRPA1 [31]. The TRPA1 antagonist, AP-18 significantly blocked the calcium response to 
100µM AITC (Fig. 7B & C) indicating that in this assay AITC stimulated exclusively TRPA1 
to increase intra-cellular calcium. The response to 100µM AITC was significantly inhibited by 
pre-treatment with VEGF-A165b for 24h (Fig. 7D & E). AITC treatment (300µM, 24h) also 
caused a significant increase in AC3 fluorescence intensity measured in 50B11 cells (Fig. 7F 
& G). 
Exposure of 50B11 cells to high glucose treatment caused a significant increase in AC3 
fluorescence intensity (Fig. 8A & B). High glucose also enhanced the level of intracellular 
calcium in response to 100µM AITC stimulation indicating either altered channel kinetics or 
altered calcium extrusion under high glucose treatment, an effect that was not attributable to 
an osmotic effect of the additional glucose (Fig. 8C & D). Treatment with VEGF-A165b 
significantly inhibited AITC-evoked calcium fluorescence under high glucose conditions (Fig. 
8E & F). Under high glucose conditions, the effect of VEGF-A165b on the calcium response 
was blocked by a VEGFR2 tyrosine kinase inhibitor (PTK787, 200nM; Fig. 8G), and a 
VEGFR2 receptor-neutralizing antibody (DC101; Fig. 8H) 
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Discussion  
Diabetic patients complain of abnormal sensations, including allodynia and hyperalgesia. 
Diabetic neuropathy is also associated with loss of sensation as peripheral sensory nerve 
terminals are lost from the dermis and epidermis. Classically these symptoms occur in the 
extremities e.g. toes, affecting more proximal regions as the disease progresses. Thus 
diabetic neuropathy is classically characterized by peripheral nerve fibre degeneration in 
both myelinated and unmyelinated sensory nerves with abnormal pain perception. STZ-
induced hyperglycaemia leads to a pronounced neuropathic pain phenotype in the rat [20], 
and high levels of blood glucose lead to the development of mechanical and cold allodynia, 
and heat hyperalgesia. Heightened pain responses may arise as a result of damage to the 
peripheral nervous system from direct actions of glucose [5], metabolite production [9], 
inflammation [33], or microvascular damage and other associated micro-environmental 
changes [34]. The observed increase in small myelinated fibre profiles in sciatic nerve trunk 
may represent large fibre neuropathy, with demyelination of larger fibres [25], and hence 
smaller apparent cross sectional area both in the nerve fibre and somata. Myelin damage 
could affect sensory fibres or motor axons, although hyperglycaemia has been shown to 
affect sensory fibres to a greater extent than motor axons [35]. Activated caspase-3 co-
expression with NF200 in DRG neurons is also consistent with this interpretation. 
Concurrent small fibre neuropathy in these animals is also indicated by the increased 
epidermal recruitment of Langerhans cells [30], and AC3 expression in the smaller diameter 
neurons. Langerhans cells are dendritic cells that increase their expression of PGP9.5 
following denervation and inflammation [36]. Changes in Langerhans cell number could be 
attributable to peripheral denervation, and/or altered capillary permeability and 
plasma/albumin extravasation resulting from local inflammatory responses.  
Both endoneurial capillary permeability and oedema can be seen in models of STZ-induced 
diabetes [37]. After 7 weeks of hyperglycaemia, the significantly increased Evans Blue 
clearance in sciatic nerve, and DRG are suggestive of an increase in neural perfusion and/or 
capillary permeability that could be attributable to hyperglycaemic microvascular damage. 
Although sensory neurons are particularly susceptible to hyperglycaemic injury [38] as they 
lack insulin-regulated glucose uptake [5], local hypoxia as a consequence of ischaemia 
resulting from damage to the vasa nervosa may also contribute to peripheral neuropathy 
[39].  
A number of diabetic complications are associated with increased (e.g. retinopathy) or 
impaired angiogenesis (e.g. neuropathy, wound healing) [40]. Total VEGF plasma levels are 
raised in symptomatic diabetic neuropathy [41, 42]. In contrast, neuronal expression of total-
VEGF-A is reduced in sensory neurons, in STZ-diabetic rats [11], and in epidermis in 
diabetic patients, where it is associated with more severe neuropathy [19]. The principal 
approach used to increase neuronal access to VEGF-A in different neuropathies has been to 
enhance local VEGF-A isoform transcription/production through gene therapy approaches 
such as intramuscular injection of plasmid, or viral vector containing VEGF-A cDNA,  
approaches that would increase either VEGF-A165a alone, or all isoforms of VEGF. This has 
been effective in animal models of diabetic [11, 43-46] neuropathy, and has had some 
success in the small number of early clinical trials to date [47, 48]. Increasing total-VEGF-A 
transcription with a zinc finger protein-transcription factor showed early preclinical promise 
[11, 45] but unfortunately failed in Phase II clinical trial [49], suggesting that a more targeted 
approach may be necessary. The use of recombinant human VEGF-A, although also 
successful in animal models, had limited success in humans, largely as a result of short half-
life and off-target effects at high doses [50]. Alternative therapeutic strategies that might 
better control the balance of isoforms, such as modulation of alternative splicing, are under 
consideration, as current strategies, where only VEGF-Axxxa is replaced could result in 
increased angiogenesis and pain [16].   
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VEGF-Axxxb is a potent neuroprotective factor for neurons including DRG [13], as is the 
alternatively spliced variant VEGF-Axxxa, in chemotherapeutic, diabetic and traumatic 
neuropathies [12, 14]. VEGF-Axxxa and VEGF-Axxxb signal through different downstream 
pathways on VEGFR2 activation, although both isoform families can act through ERK1/2 to 
exert neuroprotective actions [13]. A reduction in expression of either VEGF-A isoform family 
will therefore affect the potential for neuroprotection and/or regeneration. Systemic treatment 
with VEGF-A165b protein in vivo was able to prevent both neuropathic pain and the neuronal 
changes seen in diabetes that lead to neuropathy, possibly by restoring some of the lost 
trophic support.  
TRPA1 is a non-specific cation channel that has been implicated in the neuronal loss seen in 
diabetic [9], and chemotherapy-induced neuropathy [51]. Blockade of TRPA1 activity 
attenuates both diabetic neuropathic pain and the associated neuronal terminal loss [9]. 
TRPA1 is activated by the low formalin concentrations used in this study [52], responses that 
are sensitized at week 2, and attenuated by VEGF-A165b treatment. Importantly, TRPA1 has 
been localized to the IB4 nociceptor subset, neurons that are readily sensitized, are 
responsible for ‘hyperalgesic priming’ [53], and as we show, are affected by diabetic 
neuropathy. Furthermore, TRPA1 sensitization/activation in sensory nerve terminals can 
result in neurogenic inflammation and increased cutaneous plasma extravasation [54], thus 
suppression of sensory neuronal sensitization through TRPA1 by VEGF-A165b, acting 
through VEGFR2 [16], may also underlie the observed effect on plasma extravasation in the 
skin. VEGF-A165b can antagonize the vasodilatatory effects of VEGF-Axxxa [55] so the 
observed effect of VEGF-A165b on Evans’ Blue extravasation may also be due, at least in 
part, to direct actions on the vascular tone. 
To explore whether VEGF-A165b could exert some of its actions through TRPA1 we used an 
in vitro assay of TRPA1 sensitization. Sensory neurons compromised by a peripheral nerve 
injury (indicated by expression neuronal stress/death/degeneration markers (e.g. AC3)), 
undergo changes in excitability that underpin neuropathic pain [56]. TRP channels including 
TRPA1 contribute to peripheral C-fibre nociceptor sensitization in a range of neuropathic [51] 
and inflammatory conditions [57]. Although the exact function of TRPA1 is still debated, it 
can be considered as a “universal sensitizer” channel in peripheral nociceptors, contributing 
to mechanical [57], cold [58] and chemical pain, especially that generated by endogenous 
metabolites generated in hyperglycaemic conditions [9, 59].  
STZ-induced hyperglycaemia causes an increase in endoneurial levels of the toxic glucose 
metabolite methylglyoxal and methylglyoxal-glycated proteins (advanced glycated end 
products) [6]. Methylglyoxal is known to induce sustained TRPA1 activity under 
hyperglycaemic conditions [9, 59], and its production may produce observed sustained 
TRPA1 activation following high glucose treatment. VEGF-A165b-induced blockade of 
TRPA1-mediated calcium entry/handling in these high glucose conditions in vitro could 
therefore reduce both neuronal damage resulting from enhanced TRPA1-mediated calcium 
entry and the mechanical and thermal pain resulting from TRPA1 sensitization of peripheral 
nerve terminals. 
This study demonstrates that exogenous recombinant VEGF-A165b protein delivered 
systemically can reverse signs of diabetic neuropathy in the rat. VEGF-A165b exerted 
neuroprotective and anti-nociceptive actions on peripheral sensory neurons, possibly 
through a TRPA1-mediated mechanism. It is therefore important to determine whether 
control of VEGF-A165b levels, either through exogenous protein therapy, or control of 
alternative RNA splicing mechanisms [60] represents a possible novel therapeutic strategy 
for the treatment of multiple diabetic complications, including diabetic neuropathy.   
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Clinical perspective 
Diabetic complications such as neuropathy affect up to 50% of all diabetics. The pain 
associated with diabetic neuropathy is a large unmet clinical need due the increasing 
numbers of diabetics worldwide. Vascular endothelial growth factor-A (VEGF-A) has been 
suggested to be a possible therapeutic for diabetic neuropathy; this is a family of proteins 
generated through alternative pre-mRNA splicing that can exert different physiological 
effects. We show that human recombinant protein VEGF-A165b can ameliorate both diabetic 
neuronal injury and neuropathic pain in experimental rodents. Therapeutics that alter the 
VEGF-A isoform complement in favour of VEGF-A165b may be novel treatments for diabetic 
neuropathy.  
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Figure legends  
 
Figure 1. VEGF-A165b reverses diabetic neuropathic pain behaviours in rats.  
A. Blood glucose levels measured in the STZ-treated animals (STZ injection on day 0, open 
circles) compared to age matched naïve (vehicle injected, closed circles) animals. B. The 
body weights of the groups. Two experimental groups of diabetic (STZ) animals were treated 
with either vehicle or VEGF-A165b during week 1 (arrowhead) and treatment was continued 
biweekly until duration of the experiment.  STZ treatment led to neuropathic pain phenotypes 
in the diabetic + vehicle group, demonstrated by C. Mechanical allodynia measured by von 
Frey hair withdrawal threshold. D. cold allodynia measured by withdrawal to acetone. E. heat 
hyperalgesia measured by latency of withdrawal. F. Acute response to 0.5% formalin (0-15 
min) in diabetic rats after two weeks. VEGF-A165b treatment attenuated diabetic neuropathic 
pain (C-F). (2 way ANOVA + Bonferroni multiple comparisons test *p<0.05, **p<0.01, 
***p<0.001 compared to diabetic group, naïve n=6, diabetic n=9, diabetic + VEGF-A165b 
n=7). Note that the same symbols are used in all graphs for the different groups of animals. 
 
Figure 2. A. Primary adult DRG neurons stained for NSE-1 (green) and AC3 (red) in different 
experimental conditions. B. The percentage of AC3 expressing cells was increased by high 
glucose treatment and blocked by 18h 2.5nM VEGF-A165b treatment (n=4, scale bars = 
25µm). C. Images of L5 DRG expressing AC3 from naïve, diabetic (D & E, scale bar = 
50µm), diabetic + VEGF-A165b & negative controls. D. AC3 expression significantly 
increased in diabetic animals (n=3) but not in VEGF-A165b treated diabetic animals. E. AC3 
expression by neuronal size. AC3 expression was increased in small/medium L5 DRG 
neuronal cell bodies (<400µm2, 401-800 µm2) in diabetic animals (n=3), and was partially 
ameliorated by VEGF-A165b. F. The percentage of total neuronal cell bodies by size with an 
area less than 400µm2 was increased in diabetic animals compared to naïve. VEGF-A165b 
treatment prevented this effect of diabetes on DRG neuronal cell body cross-sectional area. 
(2 way ANOVA + Bonferroni multiple comparisons *p<0.05, **p<0.01, ***p<0.001.) 
 
Figure 3. A. AC3 expression in isolectin-B4 (IB4) positive neurons. B. The number of IB4 
positive neurons expressing AC3 was increased in diabetic and reduced in VEGF-A165b 
treated rats. C. AC3 expression in neurofilament (NF200)+ve DRG subsets. D. This was 
increased in diabetic compared to naïve was reduced in diabetics + VEGF-A165b (n=3/group, 
Kruskal Wallis test *p<0.05.) 
 
Figure 4. A. Representative images of epidermal/dermal (dashed line) nerve innervation 
(arrows) and Langerhans cells (arrowheads) stained with PGP9.5 in plantar skin from naïve, 
diabetic and VEGF-A165b treated diabetic rats. Nerves and Langerhans cells were quantified 
in the same sections. B. There was a lower dermal/epidermal border innervation density in 
diabetic animals that was reversed by VEGF-A165b treatment. C. Diabetic animals had 
increased intra-epidermal Langerhans cell numbers, which was prevented by VEGF-A165b 
treatment. (n=3, Kruskal Wallis test *p<0.05, **p<0.01, ***p<0.001. Scale bar = 50µm.) 
 
Figure 5. A-C. Sciatic nerves from naïve, diabetic and VEGF-A165b treated animals were 
stained with toluidine blue. B. Myelinated fibre cross-sectional area was reduced in diabetes, 
which was prevented by long-term systemic administration of VEGF-A165b (n=3/group, scale 
bar = 50µm). C. Myelinated nerve fibre numbers broken down by cross sectional area. D 
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Higher power image of axons demonstrating aberrant myelin morphology (* in A). E. The 
percentage of aberrant axons was increased in diabetic animals and inhibited by VEGF-
A165b treatment. Scale bars = 20µm, 10µm. F. NF200 staining of DRG neurons in normal, 
diabetic and VEGF-A165b treated animals. G. The cross-sectional area profile of NF200+ve 
DRG neuronal cell bodies was significantly different in L5 DRG of diabetic animals 
compared to naïve, a difference that was not observed with VEGF-A165b treatment. (Kruskal 
Wallis test and two way ANOVA with Bonferroni multiple comparisons test were performed. 
**p<0.01, ***p<0.001.) 
 
Figure 6. Evans blue clearance was increased in diabetic nerves and reduced by VEGF-
A165b. A. Animals were perfused with Evans blue for 2 hours and the clearance (tissue dye 
as a proportion of plasma dye concentration, per hour per gram of tissue) quantified by 
spectroscopy.  STZ increased Evans Blue clearance (n=5) that increased in diabetes and 
reduced by long-term systemic VEGF-A165b treatment in A. L3, L4 & L5 DRG, B. saphenous 
nerve and C. plantar skin (n=5, Kruskal Wallis test *p<0.05 **p<0.01). 
 
Figure 7. Cultured, differentiated 50B11 immortalised DRG neurons were loaded with the 
calcium indicator dye Fluo4, treated with the TRPA1 agonist AITC and fluorescence intensity 
measured and normalized to baseline. A. AITC evoked a concentration-dependent increase 
in intracellular calcium, (n=5). Cells were pre-treated with the TRPA1 antagonist AP-18 
(100µM). B. 50B11s express VEGFR2, which is unaltered by glucose concentration. C & D. 
The response to 100 µM AITC was blocked by AP-18. E & F. Cells were pre-treated with 
2.5nM VEGF-A165b for 24h and the calcium response to 100µM AITC measured. The TRPA1 
calcium increase was significantly reduced by overnight pre-treatment with VEGF-A165b 
(n=8). G. 50B11 cells were treated for 24h with 300µM AITC and stained for AC3. H. AC3 
fluorescence intensity was increased by AITC. (A,C-F, 2 way ANOVA + Bonferroni multiple 
comparisons test, Kruskal Wallis test and F. Mann Whitney test *p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001). 
 
Figure 8. A. Cultured, differentiated 50B11 immortalised DRG neurons were treated with 
high glucose treatment for 24h and AC3 expression determined by immunofluorescence. B. 
High glucose increased AC3 expression. C. Cells were treated with AITC after incubation in 
basal glucose medium or high glucose, and calcium measured by Fluo4 fluorescence 
intensity. D. High glucose enhanced the sustained increase in intracellular calcium in the 
presence of AITC, compared to basal glucose, which was not attributable to an osmotic 
effect, as mannitol had no effect (n=10). E. Cells were pre-treated with high glucose, with or 
without VEGF-A165b, or inhibitors and calcium measured in response to AITC. F. VEGF-
A165b blocked the increase in calcium induced by AITC in high glucose conditions (n=9), and 
this was inhibited by G. the VEGF receptor antagonist PTK787, 200nM (n=13) and H. the 
specific VEGFR2 neutralizing antibody DC101, 8.05µg/mL (n=7). All experimental culture 
conditions are displayed on the x axes. (2 way ANOVA + Bonferroni multiple comparisons 
test, Kruskal Wallis test and Mann Whitney tests *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001). 
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Summary statement (<40 words) 
Systemic treatment of diabetic rats with a novel human growth factor, VEGF-A165b, reversed 
neuropathic pain and peripheral nerve damage. 
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